NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 17 04:00PM ET
2.10
Dollar change
+0.04
Percentage change
1.94
%
Index- P/E- EPS (ttm)-6.19 Insider Own0.03% Shs Outstand3.16M Perf Week11.11%
Market Cap6.63M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float3.15M Perf Month-9.87%
Income-8.27M PEG- EPS next Q- Inst Own0.97% Short Float1.48% Perf Quarter-7.49%
Sales0.00M P/S- EPS this Y- Inst Trans-50.69% Short Ratio0.52 Perf Half Y-41.67%
Book/sh1.64 P/B1.28 EPS next Y- ROA-88.11% Short Interest0.05M Perf Year-72.19%
Cash/sh2.48 P/C0.85 EPS next 5Y- ROE-248.97% 52W Range1.68 - 14.83 Perf YTD-22.08%
Dividend Est.- P/FCF- EPS past 5Y46.71% ROI-200.74% 52W High-85.84% Beta1.99
Dividend TTM- Quick Ratio1.80 Sales past 5Y82.27% Gross Margin- 52W Low25.00% ATR (14)0.17
Dividend Ex-Date- Current Ratio1.80 EPS Y/Y TTM57.83% Oper. Margin- RSI (14)48.56 Volatility10.63% 7.91%
Employees16 Debt/Eq0.36 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price10.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q57.66% Payout- Rel Volume0.34 Prev Close2.06
Sales Surprise0.00% EPS Surprise-18.95% Sales Q/Q- EarningsMar 21 BMO Avg Volume90.02K Price2.10
SMA20-0.44% SMA50-6.29% SMA200-36.74% Trades Volume30,362 Change1.94%
Date Action Analyst Rating Change Price Target Change
Jul-28-20Downgrade Dawson James Buy → Neutral
Jan-31-18Downgrade H.C. Wainwright Buy → Neutral $5.50 → $2.70
Aug-14-17Reiterated Maxim Group Buy $4 → $5
Jul-17-17Initiated H.C. Wainwright Buy $11
Apr-14-25 07:30AM
Mar-25-25 08:30AM
07:30AM
Mar-21-25 07:30AM
Mar-06-25 07:30AM
07:30AM Loading…
Feb-04-25 07:30AM
Jan-16-25 07:30AM
Jan-14-25 07:30AM
07:15AM
Dec-17-24 10:24AM
07:35AM
Dec-16-24 07:30AM
07:15AM
Dec-03-24 03:45PM
Dec-02-24 07:30AM
07:00AM Loading…
Nov-27-24 07:00AM
Nov-19-24 07:30AM
Nov-15-24 07:30AM
Nov-14-24 07:15AM
07:15AM
Nov-08-24 07:30AM
Oct-29-24 07:30AM
Oct-24-24 07:30AM
Oct-22-24 07:30AM
Oct-16-24 07:30AM
Oct-07-24 07:30AM
Oct-03-24 07:30AM
Sep-20-24 09:00AM
Sep-16-24 07:30AM
Sep-11-24 01:00PM
07:30AM Loading…
Sep-03-24 07:30AM
Aug-16-24 09:00AM
Aug-09-24 07:30AM
Aug-01-24 09:00AM
Jul-31-24 09:53AM
Jul-15-24 10:16AM
Jul-10-24 07:23AM
Jul-09-24 02:37PM
10:04AM
07:30AM
Jun-25-24 07:30AM
Jun-14-24 07:30AM
Jun-07-24 09:00AM
Jun-05-24 08:00AM
May-31-24 07:30AM
May-29-24 07:30AM
May-24-24 07:30AM
May-23-24 07:30AM
May-21-24 12:35PM
07:30AM
May-20-24 07:30AM
May-16-24 07:30AM
May-13-24 10:54AM
May-10-24 07:30AM
May-06-24 07:30AM
Apr-25-24 07:30AM
Apr-18-24 08:30AM
Apr-15-24 03:55PM
11:18AM
07:30AM
Apr-11-24 07:30AM
Apr-03-24 07:30AM
Mar-15-24 01:53PM
07:30AM
Feb-08-24 07:30AM
Jan-26-24 09:00AM
Jan-25-24 07:30AM
Jan-08-24 07:30AM
Jan-04-24 07:30AM
Jan-02-24 07:30AM
Dec-01-23 07:30AM
Nov-30-23 11:07AM
07:30AM
Nov-17-23 04:00PM
Nov-13-23 08:12AM
07:30AM
Oct-20-23 04:00PM
09:00AM
Oct-16-23 07:30AM
Oct-13-23 09:00AM
Oct-06-23 09:00AM
Sep-25-23 07:30AM
Sep-22-23 04:00PM
Aug-24-23 05:30AM
Aug-21-23 07:30AM
Aug-11-23 10:05AM
Aug-10-23 07:30AM
Jul-19-23 07:13AM
Jul-11-23 07:30AM
Jun-29-23 08:07AM
Jun-02-23 09:00AM
May-30-23 05:00AM
May-16-23 07:30AM
May-15-23 07:30AM
May-11-23 07:30AM
May-09-23 04:05PM
May-05-23 09:05AM
May-04-23 03:54PM
07:30AM
May-03-23 07:30AM
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.